



## COLORADO

Prescription Drug  
Affordability Board

Division of Insurance

### Prescription Drug Affordability Board DRAFT Meeting Minutes

Friday, July 11, 2025; 10 am - 1 pm - Virtual Meeting

[Meeting Recording](#)

#### Meeting Attendance

##### Board Members

Dr. Gail Mizner  
Dr. Justin VandenBerg  
Dr. Amy Gutierrez  
Dr. Sami Diab  
Ms. Cathy Harshbarger

##### Board Staff

Sophie Thomas  
Kate Davidson  
Moroj Salih  
Sagun Sharma  
Callie Shelton  
Sara Stultz  
Rebecca Walker

#### Agenda

- Call to Order and Roll Call, Board Member and Director Disclosures
- Approval of May 23, 2025 Meeting Minutes
- Board and Director Updates
- Executive Session
- Public Comment
- Break
- Rulemaking Hearing: Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel

#### Call to Order, Roll Call, Board Member and Director Disclosures

Dr. Mizner called the meeting to order at 10:02 am. Dr. Mizner, Dr. Amy Gutierrez, Dr. Sami Diab, and Ms. Harshbarger were present. Dr. Justin Vandenberg joined the meeting at 10:04 am.

No Board members disclosed any stakeholder meetings. Board Director, Sophie Thomas, disclosed that staff met with Colorado Consumer Health Initiative (CCHI) and Colorado Center on Law and Policy (CCLP). Ms. Thomas also disclosed attending a Pharmaceutical Value Workshop titled “Multi-Stakeholder Perceptions on Unmet Medical Need Priorities” hosted by Brett McQueen and other researchers at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.

#### Approval of May 23, 2025 Meeting Minutes

Dr. Diab moved, and Dr. VandenBerg seconded a motion to approve the May 23, 2025 meeting minutes. Four Board members voted to approve the minutes. Ms. Harshbarger abstained from the vote because she did not attend the May 23rd meeting.

[DECISION: May 23, 2025 meeting minutes were approved at 10:04 am.](#)



## **Board and Director Updates**

Ms. Thomas noted that the Governor's Office proposed eight, non-substantive grammatical changes to the Board's 2024 Activities Summary Report. The Board approved the report as amended. The report was submitted to the General Assembly on July 1, 2025.

Ms. Thomas also informed the Board that the director from the Oregon PDAB will be speaking on their 2024 Constituent Group Engagement Report at a later Board meeting. Additionally, Ms. Thomas provided an update on the stakeholder workgroup for best practices for collecting patient information, which will begin in September 2025. The Board will also be briefed on federal policy updates that could impact PDAB at future meetings.

## **Executive Session**

At approximately 10:09 am, Ms. Harshbarger moved, and Dr. Gutierrez seconded a motion to convene an executive session to receive legal advice regarding use of data by the Board in setting an upper payment limit, pending litigation, section 24-4-105, C.R.S., and section 24-4-103(4)(a), C.R.S., pursuant to section 24-6-402(3)(a)(II), C.R.S.

**DECISION:** At 10:11 am, Board members voted to convene an executive session to receive legal advice regarding use of data by the Board in setting an upper payment limit, pending litigation, section 24-4-105, C.R.S., and section 24-4-103(4)(a), C.R.S., pursuant to section 24-6-402(3)(a)(II), C.R.S.

Executive session adjourned at 11:05 am. The Board received legal advice regarding use of data by the Board in setting an upper payment limit, pending litigation, section 24-4-105, C.R.S., and section 24-4-103(4)(a), C.R.S., pursuant to section 24-6-402(3)(a)(II), C.R.S. The Board conducted no formal business within the session.

## **Public Comment**

Starting at 11:06 am, the following individuals offered public comment to the Board:

- Bridget Dandaraw-Seritt - Advocates for Compassionate Therapy Now (ACT Now)
- Tiffany Westrich-Robertson - Ensuring Access through Collaborative Health (EACH) Coalition and Patient Inclusion Council (PIC)

## **Break**

Dr. Mizner called for a 10-minute break from 11:32 to 11:42 am.

## **Rulemaking Hearing: Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel**

The PDAB was in session for a rulemaking hearing at 11:42 am on PDAB Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel. Dr. Diab did not participate in the rulemaking hearing due to a conflict of interest with Enbrel.

Board staff outlined the procedure for the rulemaking hearing. Ms. Thomas presented the description of the rule, followed by witness testimonies from members of the public. The Board deliberated regarding these testimonies.



**COLORADO**

**Prescription Drug  
Affordability Board**

Division of Insurance

Beginning at 11:42 am, the following individuals offered testimonies to the Board on the noticed rule:

- Tiffany Westrich Roberston - Ensuring Access through Collaborative Health (EACH) Coalition and Patient Inclusion Council (PIC)
- Sophia Hennessy - Colorado Consumer Health Initiative (CCHI)
- Ingrid Pan - Pediatric Rheumatologist
- Katelin Lucariello - Pharmaceutical Research and Manufacturers of America (PhRMA)
- Melanie Kesner - Young Invincibles
- Karen Troester - Self
- Bridget Dandaraw-Seritt - Advocates for Compassionate Therapy Now (ACT Now)
- Kristy Kibler - Lupus Colorado
- Bethany Pray - Colorado Center on Law and Policy (CCLP)
- Amy Goodman - Colorado Bioscience Association (CBSA)
- Derek Flowers - Value of Care Coalition

Dr. Gutierrez moved, and Dr. Vandenberg seconded a motion to continue the rulemaking hearing on Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel to August 22, 2025.

[DECISION: At 1:00 pm, Dr. Mizner, Dr. Gutierrez, Ms. Harshbarger, and Dr. Vandenberg voted to continue the rulemaking hearing on Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel to August 22, 2025.](#)

Dr. Mizner adjourned the meeting at 1:02 pm. The next PDAB meeting will be held on Friday, August 22, 2025 at 10:00 am MT.